Cyclerion Therapeutics, Inc.
$3
▼
-3.61%
2026-04-21 06:20:02
www.cyclerion.com
NCM: CYCN
Explore Cyclerion Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.08 M
Current Price
$3
52W High / Low
$8.48 / $1.03
Stock P/E
—
Book Value
$2.38
Dividend Yield
—
ROCE
-40.99%
ROE
-39.34%
Face Value
—
EPS
$-1.11
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1
Beta
0.89
Debt / Equity
—
Current Ratio
5.15
Quick Ratio
5.15
Forward P/E
-2.22
Price / Sales
6.08
Enterprise Value
$9.06 M
EV / EBITDA
—
EV / Revenue
4.37
Rating
None
Target Price
$8
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Celularity Inc. | $1.24 | — | $35.47 M | — | -48.8% | -232.51% | $4.35 / $1.01 | $-0.71 |
| 2. | Heron Therapeutics, Inc. | $1.05 | — | $187.09 M | — | -1.59% | 209.08% | $2.61 / $0.74 | $0.07 |
| 3. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
| 4. | Arcus Biosciences, Inc. | $22.74 | — | $2.85 B | — | -42.51% | -63.26% | $26.4 / $7.06 | $5.04 |
| 5. | Pasithea Therapeutics Corp. | $0.72 | — | $18.52 M | — | -37.74% | -58.36% | $3.79 / $0.28 | $2.39 |
| 6. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
| 7. | Immunovant, Inc. | $28.53 | — | $5.81 B | — | -61.93% | -69.35% | $29.48 / $13.36 | $4.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.02 M | 0.88 M | 0.09 M | 0.08 M | 1.81 M | — |
| Operating Profit | -0.84 M | -1.01 M | -1.67 M | -1.46 M | 0.5 M | — |
| Net Profit | -0.8 M | -0.98 M | -0.32 M | -1.43 M | 0.53 M | — |
| EPS in Rs | -0.18 | -0.23 | -0.07 | -0.33 | 0.12 | -0.29 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.07 M | 2 M | 0 M | 0.3 M |
| Operating Profit | -4.97 M | -3.63 M | -9.65 M | -18.54 M |
| Net Profit | -3.53 M | -3.06 M | -5.26 M | -44.08 M |
| EPS in Rs | -0.81 | -0.71 | -1.22 | -10.18 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.98 M | 9.57 M | 13.37 M | 18.08 M |
| Total Liabilities | 0.9 M | 0.72 M | 2.09 M | 7.63 M |
| Equity | 9.09 M | 8.85 M | 11.29 M | 10.45 M |
| Current Assets | 4.63 M | 4.22 M | 8.02 M | 14.82 M |
| Current Liabilities | 0.9 M | 0.72 M | 2.09 M | 7.63 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -3.31 M | -4.33 M | -21.25 M | -40.61 M |
| Investing CF | — | 0 M | 10.4 M | 0 M |
| Financing CF | 3.32 M | 0 M | 5.02 M | 0.03 M |
| Free CF | -3.31 M | -4.33 M | -21.25 M | -40.61 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | 41.92% | 88.06% | — | — |
| Profit Margin % | -152.85% | — | -14841.08% | — |
| Operating Margin % | -181.4% | — | -6242.42% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -181.4% | — | -6220.54% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-05-16 | 1:0.05 |